The British Business Bank announced a £100 million cornerstone commitment to Apposite Healthcare Growth I, marking its largest fund investment to date and its first partnership with Apposite Capital.
The fund will focus on supporting growth-stage healthcare and life sciences companies, investing across areas including medical products, diagnostics, life sciences tools, digital health, and pharmaceutical outsourcing services. The initiative is designed to address a persistent shortage of scale-up capital for UK-based companies approaching key growth inflection points.
As a cornerstone investor, the British Business Bank aims to help the fund reach sufficient scale to attract additional institutional capital and accelerate its deployment strategy. The commitment aligns with the Bank’s broader objective of strengthening the UK’s growth-stage funding ecosystem and supporting the development of globally competitive companies.
The Bank has set a target of directing more than 60% of its venture and growth capital investments toward scale-ups and plans to support the launch of 10 new growth-stage funds over the next five years. The strategy includes making larger commitments to leading fund managers to catalyze private sector participation.
Apposite Capital, a specialist investor in healthcare and life sciences, will use the fund to back innovative UK companies with the potential to commercialize advanced technologies, improve patient outcomes, and create high-skilled jobs.
The investment reflects increasing focus on bridging funding gaps in the life sciences sector, where many companies face challenges accessing later-stage capital, often limiting their ability to scale domestically.
KEY QUOTES:
“The UK needs growth stage funding, and the Bank is stepping up to deliver this. Working with the UK’s venture capital community, we are looking to support the creation of growth stage funds capable of writing significant cheques into the next generation of UK unicorns. To help these funds launch and ensure they have the size and firepower needed, we are writing larger cheques and signalling these commitments to institutional investors, with the intention it mobilises the private sector.”
Christine Hockley, Managing Director And Co-Head Of Funds, British Business Bank
“The need for scale up funding is especially pronounced in life sciences. However, there remains a shortage of later-stage funds, meaning that many promising life sciences companies cannot fulfil their potential in the UK and may embark on premature or sub-optimal exits. Apposite’s new fund has a clear focus on growth stage investing in life sciences and will help convert world-leading UK science into global companies.”
Mark Andrews, Investment Director, Funds, Life Sciences, British Business Bank
“The commitment from the British Business Bank will enable Apposite to continue its strong track record of supporting ambitious growing companies and investing in businesses that can achieve better healthcare for more people. Apposite Healthcare Growth I will back the next generation of UK healthcare technology leaders. The UK is home to an extraordinary depth of scientific research, entrepreneurial talent, and innovative companies, yet many businesses face a persistent gap in scale-up funding. This fund will bridge that gap, enabling high potential companies to accelerate their growth, commercialise transformative technologies, improve health outcomes and support economic growth.”
Sam Gray, Managing Partner, Apposite Capital
“We’ve committed to backing our most ambitious companies, ensuring the UK leads in innovation and competes globally. This record investment into Apposite Capital delivers on that promise by giving it the financial firepower to support the UK’s most exciting healthcare tech firms scale, develop cutting edge medical products and diagnostics, and improve healthcare right across the country.”
Peter Kyle, Secretary Of State For Business And Trade
